Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Phase I/II study of tandutinib (MLN518) plus standard induction chemotherapy in newly diagnosed acute myelogeneous leukemia (AML)

DeAngleo DJ, Amrein PC, Kovacsovics TJ, Klisovic RB, Powell BL, Cooper M, Webb IJ, Stone RM. Phase I/II study of tandutinib (MLN518) plus standard induction chemotherapy in newly diagnosed acute myelogeneous leukemia (AML). Blood. 2006; 108:51a.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.